TY  - JOUR
A1  - Wenzel, Mike
A1  - Würnschimmel, Christoph
A1  - Nocera, Luigi
A1  - Collà Ruvolo, Claudia
A1  - Tian, Zhe
A1  - Saad, Fred
A1  - Briganti, Alberto
A1  - Tilki, Derya
A1  - Graefen, Markus
A1  - Roos, Frederik
A1  - Mandel, Philipp
A1  - Chun, Felix
A1  - Karakiewicz, Pierre I.
T1  - The effect of primary urological cancers on survival in men with secondary prostate cancer
T2  - The prostate
N2  - Background: To test the effect of urological primary cancers (bladder, kidney, testis, upper tract, penile, urethral) on overall mortality (OM) after secondary prostate cancer (PCa). Methods: Within the Surveillance, Epidemiology and End Results (SEER) database, patients with urological primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion with primary PCa controls. OM was compared between secondary and primary PCa patients and stratified according to primary urological cancer type, as well as to time interval between primary urological cancer versus secondary PCa diagnoses. Results: We identified 5,987 patients with primary urological and secondary PCa (bladder, n = 3,287; kidney, n = 2,127; testis, n = 391; upper tract, n = 125; penile, n = 47; urethral, n = 10) versus 531,732 primary PCa patients. Except for small proportions of Gleason grade group and age at diagnosis, PCa characteristics between secondary and primary PCa were comparable. Conversely, proportions of secondary PCa patients which received radical prostatectomy were smaller (29.0 vs. 33.5%), while no local treatment rates were higher (34.2 vs. 26.3%). After 1:4 matching, secondary PCa patients exhibited worse OM than primary PCa patients, except for primary testis cancer. Here, no OM differences were recorded. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis. Conclusions: After detailed matching for PCa characteristics, secondary PCa patients exhibit worse survival, except for testis cancer patients. The survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary urological cancer diagnosis.
KW  - bladder cancer
KW  - kidney cancer
KW  - mortality
KW  - primary prostate cancer
KW  - urological cancer
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62648
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-626482
SN  - 1097-0045
N1  - Open Access funding enabled and organized by Projekt DEAL.
N1  - Early View: Online Version before inclusion in an issue
N1  - Version of Record: http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:hebis:30:3-644859
VL  - 81
SP  - 1
EP  - 10
PB  - Wiley-Liss
CY  - New York, NY
ER  -